A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

NCT03717064 | Completed Phase 1 Results FDA Drug

• 1 other identifier: YP40218
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The main purpose of the study is to characterize the interaction between RO7049389 and the cholesterol-lowering drug, pitavastatin, in healthy volunteers. There is no intended clinical benefit to this study. The total duration of the study for each participant is approximately 12 weeks.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (12)

• Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin

  Period 1 Day 1

• Period 1: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin

  Period 1 Day 1

• Period 1: Time to Maximum Concentration (Tmax) of Pitavastatin

  Period 1 Day 1

• Period 1: Apparent Total Clearance (CL/F) of Pitavastatin

  Period 1

• Period 1: Volume of Distribution (V/F) of Pitavastatin

  Period 1 Day 1

• Period 1: Elimination Half-Life (T1/2) of Pitavastatin

  Period 1 Day 1

• Period 2: Maximum Plasma Concentration (Cmax) of Pitavastatin

  Period 2 Day 4

• Period 2: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin

  Period 2 Day 4

• Period 2: Time to Maximum Concentration (Tmax) of Pitavastatin

  Period 2 Day 4

• Period 2: Apparent Total Clearance (CL/F) of Pitavastatin

  Period 2 Day 4

• Period 2: Volume of Distribution (V/F) of Pitavastatin

  Period 2 Day 4

• Period 2: Elimination Half-Life (T1/2) of Pitavastatin

  Period 2 Day 4

Secondary Outcomes (9)

• Percentage of Participants With Adverse Events (AEs)

  From the start of Period 1 through safety follow-up (Period 2, Day 34)

• Period 2: Cmax of RO7049389

  Period 2 Days 3-4

• Period 2: AUC-tau of RO7049389

  Period 2 Days 3-4

• Period 1: Cmax of Pitavastatin Lactone

  Period 1 Day 1

• Period 1: AUC0-inf of Pitavastatin Lactone

  Period 1 Day 1

Study Arms (1)

Pitavastatin

EXPERIMENTAL

Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days. Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4.

Drug: RO7049389; Drug: Pitavastatin

Interventions

RO7049389 DRUG

RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.

Pitavastatin

Pitavastatin DRUG

Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.

Pitavastatin

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, as judged by the Investigator. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, and based on the laboratory safety test results at screening and Day -1
• Body mass index (BMI) between 18 to 30 kg/m2 (inclusive) at screening
• Female participants: 1) Must be either surgically sterile (by means of hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy) or post-menopausal for at least one year (defined as amenorrhea \>/=12 consecutive months without another cause, and confirmed by follicle-stimulating hormone (FSH) level. 2) Participants must not be pregnant or lactating.
• Male participants: 1) Female partners must not be pregnant or lactating. 2) Must agree to remain abstinent (refrain from heterosexual intercourse) or must agree to use a condom with spermicide during the treatment period and for at least 28 days after the last dose of study drug with female partners of childbearing potential. 3) Must agree to refrain from donating sperm during the treatment period and for at least 28 days after the last dose of study drug

You may not qualify if:

• Have a history or symptoms of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, oncologic or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study treatment; or of interfering with the interpretation of data
• Confirmed (based on the average of 3 separate resting BP measurements in a supine position, after at least 5 minutes rest) systolic BP greater than 140 or less than 90 mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening and Day -1
• Personal history or family history of congenital long QT syndrome and/or cardiac sudden death
• History of Gilbert's syndrome
• Participants who have had significant acute infection, e.g., influenza, local infection, acute gastrointestinal symptoms or any other clinically significant illness within two weeks of dose administration
• Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable)
• Taking any herbal medications or substances (e.g., tea) or supplements (including vitamins), or traditional Chinese medicines (TCM) or over-the-counter (OTC) medications within 14 days of first dosing or within 5 times the elimination half-life of the medication prior to first dosing, whichever is longer
• History of having received any systemic anti-neoplastic (including radiation) or immunemodulatory treatment (including systemic oral or inhaled corticosteroids) \</=6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
• Are currently enrolled in or have participated in any other clinical study involving an investigational product or in any other type of medical research within the last 30 days or 5 half lives (whichever is longer)
• Donation or loss of blood or blood products in excess of 500 mL within 3 months of screening and for the duration of the study
• Positive test for drugs of abuse (including recreational drugs) and/or positive alcohol test and/or positive cotinine test at screening and on Day -1
• Positive test at screening of any of the following: Hepatitis A virus (HAV IgM Ab), hepatitis B virus (HBsAg or HBcAb), hepatitis C virus (HCV RNA or HCV Ab) or human immunodeficiency virus (HIV-1 and HIV-2 Ab)
• History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol) and/or drug abuse within 12 months of screening
• Use of \>5 cigarettes or equivalent nicotine-containing product per day prior to screening

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (1)

Covance Research Unit - Daytona

Daytona Beach, Florida, 32117, United States

Location

MeSH Terms

Interventions

pitavastatin

Results Point of Contact

• Title: Medical Communications
• Organization: Hoffmann-La Roche

genentech@druginfo.com

1-800-821-8590

Study Officials

• Clinical Trials

  Hoffmann-LaRoche

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2018
• First Posted: October 24, 2018
• Study Start: November 7, 2018
• Primary Completion: December 17, 2018
• Study Completion: December 17, 2018
• Last Updated: January 10, 2020
• Results First Posted: January 10, 2020

Record last verified: 2019-12

Locations

US (1)